- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- Allogene Therapeutics announced the activation of clinical trials across the U.S. and Canada, aligning with the FDA on pivotal trial design.
Allogene Therapeutics is seeking designations for its cema-cel therapy and expanding its clinical trials internationally, including the ALPHA3 trial.
1 report, 1 independent
Updated Aug 15
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Allogene Therapeutics is seeking designations for its cema-cel therapy and expanding its clinical trials internationally, including the ALPHA3 trial.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Related events
- Lakefront, in collaboration with Gilead, received Orphan Drug Designation from the FDA for gamgertamig, with trials active globally.
- OS Therapies, Inc. is seeking interim and final review data submissions from regulatory bodies while attending major global investment conferences.
- The FDA granted Safe to Proceed for the Pivotal Phase 3 study of Vivace Therapeutics, Inc.
- TELIX Pharmaceuticals is conducting Phase 3 trials and seeking alignment on the New Drug Application pathway with the FDA.
- A network focused on cell and gene therapies is expanding to include sites in Northern California, involving the CA Institute for Regenerative Medicine and the FDA.